

PLEASE DO NOT REMOVE

January  
1993

# The Journal of Laryngology and Otology



Founded in 1887 by Morell Mackenzie & Norris Wolfenden

Edited by NEIL WEIR

Production Editor JENNY MUGRIDGE

Assistant Editors PATRICK BEASLEY, CAROL WENGRAF, RICHARD RAMSDEN, IOLO GRIFFITH,  
PETER RHÝS EVANS, DAVID PROOPS, VALERIE LUND & HENRY GRANT

Book Review and Abstracts Editor JOHN B. BOOTH

Emeritus Advisor in Pathology IMRICH FRIEDMANN

Advisors in Pathology BRIAN MANNERS, CHRISTOPHER MILROY, KENNETH MACCLELLAND &  
LESLEY SMALLMAN

Advisor in Audiology LINDA LUXON


Advisors in Radiology GLYN LLOYD & PETER PHELPS

Advisors in Statistics ANTHONY HUGHES & PETER KELLY

Vol 107  
No 1

# The AD 25 DIAGNOSTIC AUDIOMETER

from *Kamplex*<sup>®</sup>



The latest addition to the Kamplex range incorporates many of the more popular features found on the best selling AD27 in a lightweight low cost package.

The attractive low profile design and easy-to-read back-lit display makes this a perfect desktop audiometer. Air Conduction, Bone Conduction and Narrow-band masking in 5dB steps are available together with an extremely useful talk-through facility.

Superbly engineered for reliability and portability (with the optional case), the AD25 also offers an automatic test facility.\* A patient's audiometric results whether recorded manually or automatically may be stored and later recalled.

\*Auto Threshold complies with ISO 8253, Audiometric Test Methods

- **Robust and Portable (with optional carrying case)**
- **AC/BC/Narrow-Band Masking**
- **Pure, Warble and Pulsed Tones**
- **Clear, easy to read Back-lit Display**
- **Automatic Test Facility (Conforms to ISO 8253)**
- **Results Storage and Recall Capability**
- **Insert Masking**

## P.C.WERTH LTD

Audiology House, 45 Nightingale Lane, London SW12 8SP  
Telephone: 081-675 5151 Fax: 081-675 7577

Instrument Division Direct Line: 081-675 5157

Month after Month,  
Cover to Cover  
*The BEST in Otolaryngology*

THE  
**Laryngoscope**  
FOUNDED IN 1896

J. Gershon Spector, M.D.  
Editor

10 So. Broadway • Suite 1401  
St. Louis, MO 63102



U.S. \$100.00 per year      Outside U.S. \$120.00 per year  
Institutional Rate: U.S. \$125.00 per year • Outside U.S. \$150.00 per year

**PRESCRIBING INFORMATION.**

**Presentation** Rhinolast® is a buffered isotonic slightly viscous aqueous solution for nasal delivery of 0.14mg azelastine hydrochloride per actuation. **Uses** Rhinolast is both a mediator inhibitor and blocker for use in the treatment of perennial and seasonal allergic rhinitis, including hay fever. It is administered at doses which are not systemically active. **Dosage and Administration** Adults: One 0.14mg (0.14ml) application into each nostril twice daily. There is no evidence that dosage need be modified for the elderly. Children: There are insufficient clinical data to recommend use. **Contra-indications, warnings etc.** Contra-indications: Rhinolast is contra-indicated in patients with proven allergy to any of its components. Side-effects: Irritation of the nasal mucosa. Taste disturbance. **Use in pregnancy and lactation** Until further information is available Rhinolast is not recommended for use during pregnancy or lactation. **Overdosage** Animal studies have shown that high oral doses can produce CNS symptoms. Should this occur in man symptomatic and supportive treatment should be instigated. There is no specific antidote. **Pharmaceutical precautions** Do not store below 8°C. Do not refrigerate. **Legal category** POM. **Package quantities** Each pack of Rhinolast contains one 10ml bottle and a metered pump device. **Product Licence Holder** ASTA Medica Limited, 168 Cowley Road, Cambridge CB4 4DL. **Product Licence Number** 8336/0039. **Basic NHS Cost** 10ml - £6.40. Rhinolast® is a registered Trade Mark. ©ASTA Medica Ltd. 1992.

**REFERENCES**

1. Davies RD, Lund VJ and Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. (Data on file).
2. Kunkel G et al., Protection of a single dose of azelastine HCl nasal spray against nasal alterations induced by allergen challenge. Study no. 2752, ASTA Pharma AG, 1990.

**ASTA  
MEDICA**


**ANT**



**An H<sub>1</sub> blocker i**

ANNALS  
OTOLARYNGOLOGY

A PERFECT MATCH  
SINCE 1892



- MONTHLY ISSUES • SUPPLEMENTS
- PEER REVIEWED • CLINICAL AND RESEARCH
- IMAGING CASE STUDIES • PATHOLOGY CONSULTATIONS
- LETTERS TO THE EDITOR • BOOK REVIEWS

1993 ANNUAL SUBSCRIPTION RATES

	<u>Resident*</u>	<u>Individual*</u>	<u>Institutional</u>
US	<input type="checkbox"/> \$48.00	<input type="checkbox"/> \$ 99.00	<input type="checkbox"/> \$148.50
Foreign	<input type="checkbox"/> \$60.00	<input type="checkbox"/> \$119.00	<input type="checkbox"/> \$168.50

\*Individual, resident, and student subscriptions must be in the individual's name and must be billed to and paid for by the individual.

**NEW SUBSCRIBERS RECEIVE 2 ISSUES  
FREE WITH PAID SUBSCRIPTION**



Mail to or call:

ANNALS PUBLISHING CO  
4507 LACLEDE AVENUE  
ST LOUIS, MISSOURI 63108  
(314) 367-4987  
FAX (314) 367-4988



# HISSSTAMINE



Rhinolast is an antihisssstamine nasal ssspray with proven effectiveness in non perennial and seasonal rhinitis.

Its topical action is effective in combating the symptom complex of perennial rhinitis, notably sssneezing, blocked, running and itching nose.<sup>1</sup>


And Rhinolast is fasst acting, providing a significant reduction in sneezing attacks within minutes.<sup>2</sup>

Rhinolast. For both perennial and seasonal rhinitis sssufferers.

nasal spray.

**Rhinolast**<sup>®</sup>  
Azelastine

**IN ALLERGIC RHINITIS**



Recurrent vertigo under control means that patients can continue with their normal daily activities.

With non-sedative Serc-16, driving can be a part of that way of life — because new evidence has shown that even high doses of Serc (72mg tds) did not impair driver performance.<sup>1</sup>

Prochlorperazine (5mg tds), however, caused a significant deterioration in driving skills, of which the drivers themselves were unaware.<sup>1</sup>

The way ahead is now clear for your patients with recurrent vertigo —  
 R Serc-16 1 tds.

NON-SEDATIVE

**Serc-16**

betahistine 16mg

**THE WAY AHEAD IN RECURRENT VERTIGO**  
 due to Ménière's syndrome

Reference 1 Betts TA et al. *Br J Clin Pharmacol* 1991; 32: 455-458.

**Prescribing information**

**Presentation** A white, flat round tablet imprinted '267' on one face, 'DUPHAR' on the reverse, each tablet containing 16mg betahistine dihydrochloride. Available in packs of 84 tablets. Basic NHS price £18.03. **Indications** Vertigo, tinnitus and hearing loss associated with Ménière's syndrome. **Dosage and Administration** Adults: Initially one tablet three times daily taken preferably

with meals. Maintenance dose: 24-48mg daily. Children: No dosage recommendations are made for children. **Contra-indications, Warnings, etc.:** Contra-indications: Phaeochromocytoma. Precautions: Caution is advised in the treatment of patients with a history of peptic ulcer. Clinical intolerance to Serc in bronchial asthma patients has been shown in a relatively few patients and therefore caution should be exercised when administering betahistine to patients with bronchial asthma. The usual precautions should be observed when administering Serc to patients in pregnancy.

**Side-effects:** Relatively few side-effects have been reported. They include gastro-intestinal upset (including dyspepsia), headache, skin rash and pruritus. **Product Licence Number** 05120088. Further information is available from: Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281. Duphar, a member of the Solvay Group.

**duphar**

Rx 1 tds

The Journal of  
Laryngology and Otology



# The Journal of Laryngology and Otology

Edited by NEIL WEIR

Production Editor JENNY MUGRIDGE

Assistant Editors PATRICK BEASLEY, CAROL WENGRAF, RICHARD RAMSDEN,  
IOLO GRIFFITH, PETER RHÛS EVANS, DAVID PROOPS, VALERIE LUND &  
HENRY GRANT

Book Review and Abstracts Editor JOHN B. BOOTH

Emeritus Advisor in Pathology IMRICH FRIEDMANN

Advisors in Pathology BRIAN MANNERS, CHRISTOPHER MILROY,  
KENNETH MACCLELLAND & LESLEY SMALLMAN

Advisor in Audiology LINDA LUXON

Advisors in Radiology GLYN LLOYD & PETER PHELPS

Advisors in Statistics ANTHONY HUGHES & PETER KELLY

*FOUNDED IN 1887 BY MORELL MACKENZIE  
& NORRIS WOLFENDEN*

VOLUME 107

*Published for the Proprietors by*

HEADLEY BROTHERS LTD

Ashford, Kent TN24 8HH

1993

## The Journal of Laryngology and Otology



